Clinical Efficacy and Prognostic Factors of Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma in 38 Cases
10.3971/j.issn.1000-8578.2022.22.0034
- VernacularTitle:自体造血干细胞移植治疗霍奇金淋巴瘤38例临床疗效及预后影响因素分析
- Author:
Zhenghua HUANG
1
;
Jian ZHOU
;
Yufu LI
;
Yanyan LIU
;
Keshu ZHOU
;
Yongping SONG
Author Information
1. Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450003, China
- Publication Type:Research Article
- Keywords:
Hematopoietic stem cell transplantation;
Autologous;
Hodgkin's lymphoma;
Prognosis;
Curative effect
- From:
Cancer Research on Prevention and Treatment
2022;49(9):952-955
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and prognostic factors of autologous hematopoietic stem cell transplantation (ASCT) for Hodgkin's lymphoma (HL). Methods We retrospectively analyzed the data of 38 patients with HL who underwent ASCT. Kaplan-Meier and Cox methods were used to analyze the curative effect and prognostic factors after transplantation. Results All 38 transplanted patients obtained hematopoietic reconstitution. The CR rates before and after transplantation were 55.3% and 81.6%, respectively, and the 5-year PFS and OS were 76.1% and 79.0%, respectively. Univariate analysis showed that B symptoms, IPS score, pre-transplant remission status, extranodal invasion, and pretreatment regimen were the factors affecting the prognosis of ASCT in patients with HL. Multivariate analysis showed that B symptom was an independent risk factor affecting 5-year PFS. Conclusion ASCT is effective in the treatment of high-risk, relapsed, and refractory patients with HL. B symptom is an independent risk factor affecting the prognosis of transplantation.
